How does InvestorMatch.Pro work?

Upload your pitch deck, and our AI reads it to extract key signals about your startup's stage, sector, traction, and team. The platform then searches the internet for active venture capital investors who match those signals, returning a ranked list of the 20 best-fit investors to approach.

Is InvestorMatch.Pro free?

InvestorMatch.Pro has a free tier available. Upload your deck and get AI analysis at no cost. You only pay when you want to unlock your full personalized investor recommendations.

What types of investors does InvestorMatch.Pro find?

InvestorMatch.Pro focuses on venture capital investors across stages (pre-seed, seed, Series A, Series B) and sectors including SaaS, AI/ML, fintech, healthcare, marketplaces, consumer, and climate tech.

Who created InvestorMatch.Pro?

InvestorMatch.Pro was created by Martin Tobias, a venture capitalist at Incisive Ventures who has made 75+ pre-seed investments over 5 years and was an early investor in DocuSign. He built it as a resource for founders who lack warm introductions to VCs.

How is this different from other investor matching tools?

InvestorMatch.Pro is built by an active VC, not a marketplace. It analyzes your actual pitch deck rather than asking you to fill out a form, and it uses AI to search the live internet for investors rather than relying on a static database.

What stage does Boehringer Ingelheim Venture Fund invest at?

Boehringer Ingelheim Venture Fund invests at Seed, Series A stages.

What check size does Boehringer Ingelheim Venture Fund write?

InvestorMatch does not have a recorded check size for Boehringer Ingelheim Venture Fund. Its stage focus (Seed, Series A) is the best available signal for round size.

What sectors does Boehringer Ingelheim Venture Fund invest in?

Boehringer Ingelheim Venture Fund invests in Other, Healthcare, AI / ML.

What has Boehringer Ingelheim Venture Fund invested in recently?

Boehringer Ingelheim Venture Fund has 7+ portfolio companies, including Obulytix, Glox Therapeutics, QUANTRO Therapeutics, Abexxa Biologics, Okairos AG.

How much capital does Boehringer Ingelheim Venture Fund manage?

InvestorMatch does not have a recorded AUM figure for Boehringer Ingelheim Venture Fund.

Boehringer Ingelheim Venture Fund — Seed & Series A VC Firm

Website

Boehringer Ingelheim Venture Fund is a Seed, Series A venture capital firm investing in Other, Healthcare, AI / ML. The firm has 7 portfolio companies in our records.

Portfolio: 7 companies on record
Partners: 9 listed
Stage: Seed, Series A
Sectors: Other, Healthcare, AI / ML
Check size: Not in our records
AUM: Not in our records

Last verified: 2026-10-08

How to approach: warm intro preferred

Stage

Seed, Series A

Portfolio

7+ companies

Team

9 partners

Investor activity

Investments in last 12 months: 0

Investment Thesis

Backed digital pathology company Aignostics, indicating openness to computational pathology and translational diagnostics with pharmaceutical applications.

How Boehringer Ingelheim Venture Fund invests

Boehringer Ingelheim Venture Fund is a vc firm. The firm invests at the Seed, Series A stages, with a focus on Other, Healthcare, AI / ML.

Boehringer Ingelheim Venture Fund has backed 7 companies in our records, including Obulytix, Glox Therapeutics, QUANTRO Therapeutics.

Partners & Team

Christian Thomsen

Global External Research Director

Dustin Ensign

Director of Medical Education

Alexander Haydl

Chief AI Officer

Petra Kienle

Director of Communications

Sara Lapomarda

Senior Director, Strategic Accounts

Villum Wittrup-Jensen

Executive Director

Annegret Klocker

Head of Chemical Production

Lara Crissey

Director of Patient Advocacy

Amador Guerrero

Regional Communications Director

Industry Focus

Invests In

Other

Healthcare

AI / ML

Portfolio Companies (7)

Other

Obulytix

anti-infectives / AMR·early-stage / seed·Boehringer Ingelheim Venture Fund

Develops engineered-enzyme precision antimicrobials for antimicrobial-resistant bacterial infections

Glox Therapeutics

anti-infectives / AMR·early-stage·Boehringer Ingelheim Venture Fund

Develops precision antibiotic therapies based on bacteriocins to target AMR bacteria

QUANTRO Therapeutics

oncology / therapeutics·seed·Boehringer Ingelheim Venture Fund

Therapeutics company with a seed financing round that explicitly included Boehringer Ingelheim Venture Fund

Abexxa Biologics

oncology / biopharma·research stage·Boehringer Ingelheim Venture Fund

Research-stage biopharmaceutical company developing antibody-based cancer therapies

Okairos AG

vaccines / infectious disease·clinical stage·Boehringer Ingelheim Venture Fund

Clinical-stage vaccine company working on malaria and hepatitis C programs

ProTgen

cell therapy / immunology·not specified on the portfolio page·Boehringer Ingelheim Venture Fund

Develops an in vitro platform to generate progenitor T cells from hematopoietic stem cells

Smartbax GmbH

anti-infectives / AMR·not specified on the portfolio page·Boehringer Ingelheim Venture Fund

Develops novel anti-bacterial modes of action to overcome resistance and induce bacterial self-destruction

How to pitch Boehringer Ingelheim Venture Fund

•Raising at Seed, Series A? You're squarely in their sweet spot.
•Lead with your fit in Other, Healthcare, AI / ML — the sectors they actively back.
•warm intro preferred
•Address your outreach to a specific partner, such as Christian Thomsen, Global External Research Director.
•A warm introduction beats a cold email. Get matched and request an intro.